Sarcoma of the Bladder and Prostate

Narayana, Ambati S.; Loening, Stefan A.; Weimar, George W.; Culp, David A.

doi:10.1016/s0022-5347(17)57387-5

Cited by 40 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of neoadjuvant and adjuvant treatments (radiotherapy [RT], chemotherapy) is not defined, and the indications are often based on institutional preference or by analogy with soft tissue sarcoma (eg, limb or retroperitoneal) recommendations. Data from the available literature are limited: the number of patients is often small (4‐23 patients), often including also metastatic situations, diagnostic and treatment modalities are often inhomogeneous, and some patients were likely treated in different eras (eg, >60 years prior). This influences the analysis of clinical outcomes and the choice of the therapeutic approach to PS.…”

Section: Introductionmentioning

confidence: 99%

Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Radical resection has been suggested to be the main therapeutic strategy for localized prostatic sarcoma in general [15][16][17]. A single case of radiation-induced intermediate-grade spindle cell prostatic sarcoma treated with isolated pelvic perfusion using cisplatin followed by pelvic exenteration has been reported [10].…”

Section: Discussionmentioning

confidence: 99%

Postradiation High-Grade Myofibroblastic Sarcoma of the Prostate – a Rare Entity of Prostatic Tumors – Responding to Liposomal Doxorubicin

Joerger

Oehlschlegel²,

Cerny³

et al. 2002

Oncol Res Treat

View full text Add to dashboard Cite

Background: Prostatic postradiation sarcoma (PRS) is a very rare malignant disease with a dismal prognosis. Aggressive surgical resection is the most widely used therapy for PRS. Chemotherapy so far has been unsatisfactory, with doxorubicin being the only drug with established activity. Liposomal doxorubicin has been shown to have comparable activity and a more favorable toxicity profile compared with unpegylated doxorubicin. Case report: A 78-year-old man presented with high-grade myofibroblastic sarcoma 13 years after curatively intended pion irradiation of the prostate with 30 Gy. He was treated with liposomal doxorubicin 40 mg/m² every 4–6 weeks up to now with a total dose of 800 mg. Partial remission has been achieved after 17 months of treatment with liposomal doxorubicin. Toxicity is minimal with palmoplantar erythrodysesthesia WHO grade 1, resolving completely after extending treatment intervals to 6 weeks. Result: Liposomal doxorubicin led to a sustained tumor stabilization over 17 months in a patient with prostatic postradiation high-grade sarcoma. Postradiation sarcoma (PRS) usually has a dismal prognosis and only very limited therapeutic possibilities. As in sarcomas of different origin, anthracyclines including liposomal doxorubicin seem to have potential antitumor activity in postradiation sarcoma of the prostate.

show abstract

“…In Christofferson' s [5] literature review of 59 patients, the survival after 1 year was 55 % and after 3 years 22 %. Narayana et al [9] stated that 5 of 10 men observed survived more than 5 years, but 4 pre sented tumor recurrence.…”

Section: Casementioning

confidence: 99%

“…The limited effective ness of surgery and radiation has been observed, and multimodal treatment modalities may increase survival, but again no protocol is currently available because of the rarity of the disease [9], Indeed, for the more common pelvic rhabdomyosarcoma in children, initial reduction of the tumor mass by chemotherapy and radiotherapy fol lowed by surgery has produced increased survival rates [12].…”

Section: Casementioning

confidence: 99%